Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

NCT06930859 · clinicaltrials.gov ↗

RECRUITING

Status

2766

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ribociclib
DRUG: Letrozole
DRUG: Anastrozole

Sponsor

Novartis Pharmaceuticals